This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Apr;10(4):182.

doi: 10.1038/nrneurol.2014.48. Epub 2014 Mar 18.

Multiple sclerosis: Atacicept increases relapse rates in multiple sclerosis

PMID: 24638130
DOI: 10.1038/nrneurol.2014.48

Comment

Multiple sclerosis: Atacicept increases relapse rates in multiple sclerosis

Ellen Bible. Nat Rev Neurol. 2014 Apr.

. 2014 Apr;10(4):182.

doi: 10.1038/nrneurol.2014.48. Epub 2014 Mar 18.

Author

PMID: 24638130
DOI: 10.1038/nrneurol.2014.48

No abstract available

PubMed Disclaimer

Comment on

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
Kappos L, Hartung HP, Freedman MS, Boyko A, Radü EW, Mikol DD, Lamarine M, Hyvert Y, Freudensprung U, Plitz T, van Beek J; ATAMS Study Group. Kappos L, et al. Lancet Neurol. 2014 Apr;13(4):353-63. doi: 10.1016/S1474-4422(14)70028-6. Epub 2014 Mar 6. Lancet Neurol. 2014. PMID: 24613349 Clinical Trial.

References

1. Lancet Neurol. 2014 Apr;13(4):353-63 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.